141 related articles for article (PubMed ID: 26788853)
21. Structural determinants of MALT1 protease activity.
Wiesmann C; Leder L; Blank J; Bernardi A; Melkko S; Decock A; D'Arcy A; Villard F; Erbel P; Hughes N; Freuler F; Nikolay R; Alves J; Bornancin F; Renatus M
J Mol Biol; 2012 May; 419(1-2):4-21. PubMed ID: 22366302
[TBL] [Abstract][Full Text] [Related]
22. The T-cell fingerprint of MALT1 paracaspase revealed by selective inhibition.
Bardet M; Unterreiner A; Malinverni C; Lafossas F; Vedrine C; Boesch D; Kolb Y; Kaiser D; Glück A; Schneider MA; Katopodis A; Renatus M; Simic O; Schlapbach A; Quancard J; Régnier CH; Bold G; Pissot-Soldermann C; Carballido JM; Kovarik J; Calzascia T; Bornancin F
Immunol Cell Biol; 2018 Jan; 96(1):81-99. PubMed ID: 29359407
[TBL] [Abstract][Full Text] [Related]
23. Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity.
Jaworski M; Marsland BJ; Gehrig J; Held W; Favre S; Luther SA; Perroud M; Golshayan D; Gaide O; Thome M
EMBO J; 2014 Dec; 33(23):2765-81. PubMed ID: 25319413
[TBL] [Abstract][Full Text] [Related]
24. Chemical Probes for Profiling of MALT1 Protease Activity.
Verhelst SHL; Prothiwa M
Chembiochem; 2023 Nov; 24(21):e202300444. PubMed ID: 37607867
[TBL] [Abstract][Full Text] [Related]
25. Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.
Lim SM; Jeong Y; Lee S; Im H; Tae HS; Kim BG; Park HD; Park J; Hong S
J Med Chem; 2015 Nov; 58(21):8491-502. PubMed ID: 26496175
[TBL] [Abstract][Full Text] [Related]
26. MALT1 cleaves the E3 ubiquitin ligase HOIL-1 in activated T cells, generating a dominant negative inhibitor of LUBAC-induced NF-κB signaling.
Elton L; Carpentier I; Staal J; Driege Y; Haegman M; Beyaert R
FEBS J; 2016 Feb; 283(3):403-12. PubMed ID: 26573773
[TBL] [Abstract][Full Text] [Related]
27. MALT1 paracaspase is overexpressed in hepatocellular carcinoma and promotes cancer cell survival and growth.
Kurden-Pekmezci A; Cakiroglu E; Eris S; Mazi FA; Coskun-Deniz OS; Dalgic E; Oz O; Senturk S
Life Sci; 2023 Jun; 323():121690. PubMed ID: 37059355
[TBL] [Abstract][Full Text] [Related]
28. Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation.
Gewies A; Gorka O; Bergmann H; Pechloff K; Petermann F; Jeltsch KM; Rudelius M; Kriegsmann M; Weichert W; Horsch M; Beckers J; Wurst W; Heikenwalder M; Korn T; Heissmeyer V; Ruland J
Cell Rep; 2014 Nov; 9(4):1292-305. PubMed ID: 25456129
[TBL] [Abstract][Full Text] [Related]
29. Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies.
Juilland M; Thome M
Curr Opin Hematol; 2016 Jul; 23(4):402-9. PubMed ID: 27135977
[TBL] [Abstract][Full Text] [Related]
30. The Paracaspase MALT1.
Hachmann J; Salvesen GS
Biochimie; 2016 Mar; 122():324-38. PubMed ID: 26386283
[TBL] [Abstract][Full Text] [Related]
31. Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity.
Zhou H; Du MQ; Dixit VM
Cancer Cell; 2005 May; 7(5):425-31. PubMed ID: 15894263
[TBL] [Abstract][Full Text] [Related]
32. The paracaspase MALT1 cleaves the LUBAC subunit HOIL1 during antigen receptor signaling.
Douanne T; Gavard J; Bidère N
J Cell Sci; 2016 May; 129(9):1775-80. PubMed ID: 27006117
[TBL] [Abstract][Full Text] [Related]
33. MALT1 inhibitors prevent the development of DSS-induced experimental colitis in mice via inhibiting NF-κB and NLRP3 inflammasome activation.
Liu W; Guo W; Hang N; Yang Y; Wu X; Shen Y; Cao J; Sun Y; Xu Q
Oncotarget; 2016 May; 7(21):30536-49. PubMed ID: 27105502
[TBL] [Abstract][Full Text] [Related]
34. Activity-based probes for detection of active MALT1 paracaspase in immune cells and lymphomas.
Eitelhuber AC; Vosyka O; Nagel D; Bognar M; Lenze D; Lammens K; Schlauderer F; Hlahla D; Hopfner KP; Lenz G; Hummel M; Verhelst SH; Krappmann D
Chem Biol; 2015 Jan; 22(1):129-38. PubMed ID: 25556945
[TBL] [Abstract][Full Text] [Related]
35. Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma.
Nie Z; Du MQ; McAllister-Lucas LM; Lucas PC; Bailey NG; Hogaboam CM; Lim MS; Elenitoba-Johnson KS
Nat Commun; 2015 Jan; 6():5908. PubMed ID: 25569716
[TBL] [Abstract][Full Text] [Related]
36. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20.
Coornaert B; Baens M; Heyninck K; Bekaert T; Haegman M; Staal J; Sun L; Chen ZJ; Marynen P; Beyaert R
Nat Immunol; 2008 Mar; 9(3):263-71. PubMed ID: 18223652
[TBL] [Abstract][Full Text] [Related]
37. MALT1 is not alone after all: identification of novel paracaspases.
Hulpiau P; Driege Y; Staal J; Beyaert R
Cell Mol Life Sci; 2016 Mar; 73(5):1103-16. PubMed ID: 26377317
[TBL] [Abstract][Full Text] [Related]
38. Targeting B-cell lymphomas with inhibitors of the MALT1 paracaspase.
Hailfinger S; Lenz G; Thome M
Curr Opin Chem Biol; 2014 Dec; 23():47-55. PubMed ID: 25285878
[TBL] [Abstract][Full Text] [Related]
39. Development of new Malt1 inhibitors and probes.
Xin BT; Schimmack G; Du Y; Florea BI; van der Marel GA; Driessen C; Krappmann D; Overkleeft HS
Bioorg Med Chem; 2016 Aug; 24(15):3312-29. PubMed ID: 27085674
[TBL] [Abstract][Full Text] [Related]
40. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.
Quancard J; Klein T; Fung SY; Renatus M; Hughes N; Israël L; Priatel JJ; Kang S; Blank MA; Viner RI; Blank J; Schlapbach A; Erbel P; Kizhakkedathu J; Villard F; Hersperger R; Turvey SE; Eder J; Bornancin F; Overall CM
Nat Chem Biol; 2019 Mar; 15(3):304-313. PubMed ID: 30692685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
